Ginsburg J, Hardiman P, Thomas M
Department of Endocrinology, Royal Free Hospital School of Medicine, London, UK.
Gynecol Endocrinol. 1992 Jun;6(2):119-26. doi: 10.3109/09513599209046395.
Adverse effects occur in over 50% of women taking oral bromocriptine, causing at least 10% to discontinue treatment. Although the drug is absorbed from the vagina and reportedly caused no side-effects in one patient intolerant of oral bromocriptine, long-term clinical effects of daily vaginal administration have not been assessed. We have now given bromocriptine vaginally for up to 2 years to 31 hyperprolactinemic and five normoprolactinemic women, 17 of whom were intolerant of oral bromocriptine. The drug was well absorbed from the vagina and a daily dosage of 2.5 mg lowered serum prolactin levels in 28 of the hyperprolactinemic women (in 11 to within normal limits), restored menstrual cyclicity, and abolished galactorrhea; one of the four infertile women conceived. Minor side-effects occurred in only three women. Vaginal administration is clinically effective, avoids the adverse effects of oral therapy and could be the first-line treatment for patients requiring bromocriptine.
超过50%服用口服溴隐亭的女性会出现不良反应，至少10%的女性因此停药。尽管该药物可经阴道吸收，且据报道，一名不耐受口服溴隐亭的患者经阴道用药未出现副作用，但每日经阴道给药的长期临床效果尚未得到评估。我们现已对31名高泌乳素血症女性和5名泌乳素水平正常的女性经阴道给予溴隐亭长达2年，其中17名女性不耐受口服溴隐亭。药物经阴道吸收良好，每日2.5毫克的剂量使28名高泌乳素血症女性的血清泌乳素水平降低（11名降至正常范围），恢复了月经周期，消除了溢乳；4名不孕女性中有1名怀孕。仅3名女性出现轻微副作用。经阴道给药临床有效，避免了口服治疗的不良反应，可能成为需要使用溴隐亭患者的一线治疗方法。
